Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19808699 | 0.88 | EPHX2 (0.43) | CA2EPHX2CA12CA7CA9 | |
| SCHEMBL19808702 | 0.86 | CA12 (0.34) | CA2EPHX2CA12CA7CA9 | |
| SCHEMBL19808619 | 0.83 | CA2 (0.41) | CA2CA1EPHX2CA12CA7 | |
| SCHEMBL20724755 | 0.80 | ALDH1A1 (0.44) | EPHX2 | |
| SCHEMBL19808656 | 0.79 | KDM4E (0.33) | EPHX2 | |
| SCHEMBL20724769 | 0.78 | CA2 (0.33) | CA2CA1CA12CA7CA9 | |
| SCHEMBL19807169 | 0.78 | SMN1; SMN2 (0.38) | CA2CA1 | |
| SCHEMBL19798462 | 0.71 | EPHX2 (0.54) | CA2EPHX2CA12CA7CA9 | |
| SCHEMBL19808235 | 0.71 | CA12 (0.35) | CA2CA12CA7CA9CA14 | |
| SCHEMBL19798466 | 0.70 | EPHX2 (0.41) | CA2EPHX2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | CA2 1563/4885CA1 1754/4885EPHX2 1124/4885 |
| US-20180022752-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | IDO1, IDO2, TDO2 | CA2 1563/4885CA1 1754/4885EPHX2 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.